| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GAGE2D |
| Uniprot No | Q9UEU5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-116aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMSWRGRS TYRPRPRRYV EPPEMIGPMR PEQFSDEVEP ATPEEGEPAT QRQDPAAAQE GEDEGASAGQ GPKPEADSQE QGHPQTGCEC EDGPDGQEMD PPNPEEVKTP EEGEKQSQC |
| 预测分子量 | 15 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GAGE2D重组蛋白的3篇参考文献示例：
---
1. **文献名称**：*GAGE2D Recombinant Protein Expression and Its Immunogenic Potential in Cancer Cells*
**作者**：Smith A, et al.
**摘要**：研究报道了GAGE2D重组蛋白在大肠杆菌中的高效表达及纯化，验证了其在多种肿瘤细胞中的异常高表达，并证明其能诱导体外T细胞免疫反应，提示其作为癌症疫苗抗原的潜力。
---
2. **文献名称**：*Functional Characterization of GAGE2D in Apoptosis Resistance via Recombinant Protein Overexpression*
**作者**：Zhang L, et al.
**摘要**：通过构建GAGE2D重组蛋白的真核表达系统，发现其过表达可抑制肿瘤细胞凋亡，增强化疗耐药性，机制可能与调控Bcl-2家族蛋白表达相关。
---
3. **文献名称**：*GAGE2D as a Novel Cancer-Testis Antigen: Recombinant Protein-Based Serological Analysis*
**作者**：Kim H, et al.
**摘要**：利用重组GAGE2D蛋白进行血清学检测，发现其在卵巢癌和肺癌患者血清中特异性抗体水平显著升高，提示其作为液体活检标志物的临床应用价值。
---
注：上述文献为示例，实际引用需根据具体研究调整。若需真实文献，建议通过PubMed或Google Scholar以关键词“GAGE2D recombinant”检索近年研究。
GAGE2D is a member of the GAGE (G antigen) family of proteins, which are classified as cancer-testis antigens (CTAs) due to their restricted expression in normal testicular germ cells and frequent reactivation in various cancers. The GAGE family comprises multiple paralogs clustered on chromosome X, exhibiting high sequence homology but distinct functional roles. GAGE2D, encoded by the *GAGE2D* gene, shares a conserved structure with other GAGE proteins, typically characterized by a conserved C-terminal domain and variable N-terminal regions. These proteins are implicated in oncogenesis, immune evasion, and tumor progression, though their precise molecular mechanisms remain under investigation.
Recombinant GAGE2D protein is artificially produced using genetic engineering techniques, often expressed in bacterial or mammalian systems to ensure proper folding and post-translational modifications. Its production enables functional studies, antibody development, and therapeutic exploration. As a CTA, GAGE2D is of particular interest in cancer immunotherapy due to its tumor-specific expression, which may allow it to serve as a target for T-cell-based therapies or vaccines. Its immunogenicity and potential to elicit immune responses make it a candidate biomarker for cancer diagnosis and prognosis.
Research on recombinant GAGE2D also focuses on understanding its interaction with immune checkpoints, epigenetic regulation in cancer cells, and role in chemotherapy resistance. However, challenges persist, including its low immunogenicity in some patients and homology-driven cross-reactivity with other GAGE family members. Despite these hurdles, recombinant GAGE2D remains a valuable tool for deciphering tumor biology and advancing personalized oncology therapies.
×
